ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In conclusion, our findings in these two studies warrant that niclosamide may represent a promising chemotherapeutic agent in the imatinib-resistant CML patient subpopulation harboring T315I-BCR-ABL and/or LSCs, and deserve a clinic trial.